Preclinical studies examining advanced cancer models have previously shown that the activation of TGFb- and EMT-related pathways, along with fibroblast proliferation, leads to inhibition of T cell-mediated tumor killing and reduced T-cell mobility within the tumor [25, 43]. This evidence concerns the gene TGFB1 and neoplasm.